Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Zai Lab Acquires Global Rights to ADC for Small Cell Lung Cancer from MediLink

publication date: May 1, 2023

Shanghai Zai Lab signed a worldwide license agreement to develop a DLL3 ADC for small cell lung cancer and neuroendocrine tumors that was discovered by Boston’s MediLink Therapeutics. DLL3 inhibits the Notch ligand, which is overexpressed in the two indications. MediLink’s next-gen TAMLIN® platform is designed to leverage the tumor microenvironment to overcome the challenges in current ADC drugs. Zai agreed to pay unspecified upfront fees, milestones and tiered royalties on sales. The company will also be responsible for all global development and commercialization activities. More details....

Stock Symbols: (NSDQ:  ZLAB; HK: 9688)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital